Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 31;14(11):2719.
doi: 10.3390/cancers14112719.

Impact of Insulin Therapies on Cancer Incidence in Type 1 and Type 2 Diabetes: A Population-Based Cohort Study in Reggio Emilia, Italy

Massimo Vicentini  1 , Paola Ballotari  1 , Francesco Venturelli  1 , Marta Ottone  1 , Valeria Manicardi  2 , Marco Gallo  3 , Marina Greci  4 , Mirco Pinotti  5 , Annamaria Pezzarossi  1 , Paolo Giorgi Rossi  1
Affiliations

Impact of Insulin Therapies on Cancer Incidence in Type 1 and Type 2 Diabetes: A Population-Based Cohort Study in Reggio Emilia, Italy

Massimo Vicentini et al. Cancers (Basel). .

Abstract

Objective: To assess the effect of insulin on cancer incidence in type 1 (T1DM) and type 2 diabetes (T2DM).

Methods: The cohort included all 401,172 resident population aged 20-84 in December 2009 and still alive on December 2011, classified for DM status. Drug exposure was assessed for 2009-2011 and follow up was conducted from 2012 to 2016 through the cancer registry. Incidence rate ratios (IRRs) were computed for all sites and for the most frequent cancer sites.

Results: among residents, 21,190 people had diabetes, 2282 of whom were taking insulin; 1689 cancers occurred, 180 among insulin users. The risk for all site was slightly higher in people with T2DM compared to people without DM (IRR 1.21, 95% CI 1.14-1.27), with no excess for T1DM (IRR 0.73, 95% CI 0.45-1.19). The excess in T2DM remained when comparing with diet-only treatment. In T2DM, excess incidence was observed for liver and pancreas and for NETs: 1.76 (95% CI 1.44-2.17) and 1.37 (95% CI 0.99-1.73), respectively. For bladder, there was an excess both in T1DM (IRR 3.00, 95% CI 1.12, 8.02) and in T2DM (IRR1.27, 95% CI 1.07-1.50).

Conclusions: Insulin was associated with a 20% increase in cancer incidence. The risk was higher for liver, pancreatic, bladder and neuroendocrine tumours.

Keywords: cancer; diabetes; glucose-lowering therapies; insulin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study timeline showing the exposure assessment follow up periods.
See this image and copyright information in PMC

References

    1. Bowker S.L., Pohar S.L., Johnson J.A. A cross-sectional study of health-related quality of life deficits in individuals with comorbid diabetes and cancer. Health Qual. Life Outcomes. 2006;4:17. doi: 10.1186/1477-7525-4-17. - DOI - PMC - PubMed
    1. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L., Pollak M., Regensteiner J.G., Yee D. Diabetes and Cancer: A Consensus Report. CA Cancer J. Clin. 2010;60:207–221. doi: 10.3322/caac.20078. - DOI - PubMed
    1. Michels K.B., Solomon C.G., Hu F.B., Rosner B.A., Hankinson S.E., Colditz G.A., Manson J.E. Type 2 diabetes and subsequent incidence of breast cancer in the nurses’ health study. Diabetes Care. 2003;26:1752–1758. doi: 10.2337/diacare.26.6.1752. - DOI - PubMed
    1. Coughlin S.S., Calle E.E., Teras L.R., Petrelli J., Thun M.J. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am. J. Epidemiol. 2004;159:1160–1167. doi: 10.1093/aje/kwh161. - DOI - PubMed
    1. Weiderpass E., Persson I., Adami H.O., Magnusson C., Lindgren A., Baron J.A. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden) Cancer Causes Control. 2000;11:185–192. doi: 10.1023/A:1008946825313. - DOI - PubMed

LinkOut - more resources